NousQ Pte Ltd Secures $1.2M Seed Round to Revolutionize Patient-Centric Medical Innovation

NousQ Pte Ltd, a dynamic start-up based in Singapore, is thrilled to announce the successful closure of its Seed Round, raising over USD 1.2 million to further its mission of revolutionizing healthcare. Originally pivoting in July 2021, the company has dedicated itself to designing, developing, manufacturing, and commercializing patient-centric medical technology and devices that truly meet the needs of those seeking better care. This latest funding milestone is a testament to the confidence investors have in NousQ’s vision to optimize healthcare delivery for existing patients while also reaching the millions who currently face barriers to accessing quality care. With this substantial capital infusion, NousQ plans to accelerate the development and commercialization of its innovative product portfolio, including the much-anticipated Clikx device. The first-in-man pilot clinical trial for Clikx is set to commence in 2022 in Singapore, marking a significant step towards proving its safety and efficacy in a real-world clinical setting. Beyond technological advancement, the funding will empower NousQ to build robust partnerships with key stakeholders, fostering a sustainable enterprise dedicated to bringing hope and high-quality medical solutions to patients around the globe. As healthcare challenges evolve, NousQ Pte Ltd remains resolute in its drive to not only cater to current patient needs but also to pioneer accessible solutions for those underserved by traditional healthcare systems. This funding round is not just a financial boost—it symbolizes a collaborative leap towards a future where innovation meets compassion, ensuring that every patient, regardless of circumstance, has the opportunity to receive the care they deserve.